When focusing upon paraneoplastic neurological syndromes (characterized by anti-Hu, -Yo, -Ri, -Ma, -Ta or -Tr antibodies either in serum or CSF, and by a CNS acute inflammation), a monospecific MRZ response was present in 7/34 vs. 0/42 in MS, whereas a bispecific or a trispecific response was obtained in none (0/34) of these syndromes vs. 37/42 MS patients (55). Here, CDR2 is linked to myeloid sarcoma.